Indian Journal of Gastroenterology最新文献

筛选
英文 中文
Current practices for endoscopic management of achalasia cardia: A multicenter survey across tertiary care centers in India. 贲门失弛缓症内镜治疗的当前实践:印度三级医疗中心的多中心调查。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-27 DOI: 10.1007/s12664-025-01818-z
Zaheer Nabi, Shubra Mishra, Pradev Inavolu, D Nageshwar Reddy
{"title":"Current practices for endoscopic management of achalasia cardia: A multicenter survey across tertiary care centers in India.","authors":"Zaheer Nabi, Shubra Mishra, Pradev Inavolu, D Nageshwar Reddy","doi":"10.1007/s12664-025-01818-z","DOIUrl":"https://doi.org/10.1007/s12664-025-01818-z","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib. 托法替尼治疗溃疡性结肠炎患者的内镜组织学结果。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-24 DOI: 10.1007/s12664-025-01779-3
Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood
{"title":"Endo-histologic outcomes in patients with ulcerative colitis responding to tofacitinib.","authors":"Arshdeep Singh, Arshia Bhardwaj, Devanshi Jain, Riya Sharma, Dharmatma Singh, Ramit Mahajan, Kirandeep Kaur, Aminder Singh, Vikram Narang, Harpreet Kaur, Manavjot Singh, Pritish Gupta, Tanisha Sehgal, Vandana Midha, Ajit Sood","doi":"10.1007/s12664-025-01779-3","DOIUrl":"https://doi.org/10.1007/s12664-025-01779-3","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic target for ulcerative colitis (UC) has shifted towards deeper disease control. The real-world data on efficacy of tofacitinib in inducing histologic remission (HR) remains limited. We evaluated the real-world efficacy of tofacitinib in achieving endoscopic remission (ER) and HR.</p><p><strong>Methods: </strong>A prospective observational cohort study was conducted from January 2022 to June 2024. Adult patients with moderate-to-severe UC (Mayo score ≥ 6, endoscopic subscore ≥ 2) who responded to tofacitinib induction by week 16 were included. Paired endoscopic and histologic assessments were performed at baseline and week 48. Endoscopic disease activity was graded using the Mayo endoscopic score (MES), while histologic activity was evaluated using the Nancy index (NI). The primary outcome was combined endoscopic-histologic remission (EHR), defined as MES of 0 and a NI of 0, at week 48. The key secondary outcomes included ER, HR, histologic endoscopic mucosal improvement (HEMI) and endoscopic improvement histologic remission (EIHR).</p><p><strong>Results: </strong>Total 86 patients who received tofacitinib induction therapy were evaluated. Nine non-responders at 16 weeks were excluded and 77 patients (median age 37 years, 38 [49%] females) were analyzed. At week eight, clinical response and remission were achieved in 66 (85.7%) and 37 (48.1%) patients, respectively. At week 48, 57 (74.02%) patients maintained clinical response. Median MES and NI were 1 (IQR 0-3) and 3 (IQR 0-3), respectively. Combined EHR was achieved in 22 (28.6%) patients, while ER and HR were observed in 30 (38.9%) and 29 (37.6%) patients, respectively. HEMI was noted in 32 (41.6%) patients, while EIHR was seen in 27 (35.1%) patients. No significant predictors of ER, HR or combined EHR were identified. No serious adverse effects were reported.</p><p><strong>Conclusions: </strong>Tofacitinib is effective in achieving combined EHR, ER and HR. These findings support the potential for histologic healing as a therapeutic target for UC in real world.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical profile and manometry characteristics of patients with motor dysphagia. 运动性吞咽困难患者的临床特征和测压特征。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-20 DOI: 10.1007/s12664-025-01810-7
Mayank Jain
{"title":"Clinical profile and manometry characteristics of patients with motor dysphagia.","authors":"Mayank Jain","doi":"10.1007/s12664-025-01810-7","DOIUrl":"10.1007/s12664-025-01810-7","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary lipoarabinomannan for gastrointestinal tuberculosis: Another tool in the kit. 尿脂阿拉伯糖甘露聚糖用于胃肠道结核:试剂盒中的另一个工具。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-19 DOI: 10.1007/s12664-025-01795-3
Julajak Limsrivilai
{"title":"Urinary lipoarabinomannan for gastrointestinal tuberculosis: Another tool in the kit.","authors":"Julajak Limsrivilai","doi":"10.1007/s12664-025-01795-3","DOIUrl":"https://doi.org/10.1007/s12664-025-01795-3","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urinary lipoarabinomannan: A novel diagnostic tool for distinguishing gastrointestinal tuberculosis from Crohn's disease. 尿脂阿拉伯糖甘露聚糖:一种区分胃肠道结核和克罗恩病的新诊断工具。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-19 DOI: 10.1007/s12664-025-01764-w
Mukesh Singh, Manjeet Kumar Goyal, Himanshu Narang, Malambo Mubbunu, Peeyush Kumar, Bhaskar Kante, Sudheer K Vuyyuru, Ashish Dutt Upadhyay, Prasenjit Das, Ankur Goyal, Raju Sharma, Urvashi B Singh, Govind Makharia, Saurabh Kedia, Vineet Ahuja
{"title":"Urinary lipoarabinomannan: A novel diagnostic tool for distinguishing gastrointestinal tuberculosis from Crohn's disease.","authors":"Mukesh Singh, Manjeet Kumar Goyal, Himanshu Narang, Malambo Mubbunu, Peeyush Kumar, Bhaskar Kante, Sudheer K Vuyyuru, Ashish Dutt Upadhyay, Prasenjit Das, Ankur Goyal, Raju Sharma, Urvashi B Singh, Govind Makharia, Saurabh Kedia, Vineet Ahuja","doi":"10.1007/s12664-025-01764-w","DOIUrl":"https://doi.org/10.1007/s12664-025-01764-w","url":null,"abstract":"<p><strong>Background: </strong>The differentiation between gastrointestinal tuberculosis (GITB) and Crohn's disease (CD) is challenging. Detection of urinary lipoarabinomannan (LAM), a glycolipid component of the Mycobacterium tuberculosis cell wall, has shown potential as a non-invasive diagnostic marker for tuberculosis.</p><p><strong>Objective: </strong>We evaluated the diagnostic accuracy of urinary LAM in distinguishing GITB from CD.</p><p><strong>Methods: </strong>This prospective study included patients diagnosed with GITB, CD or those with indeterminate conditions (January 2021 to April 2022). Comprehensive clinical evaluations, laboratory investigations, computed tomography (CT) enterography, colonoscopy and histopathological analyses were performed. First morning midstream urine samples were collected and analyzed using TB LAM antigen kit. The analytical team was blinded from the clinical data. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall diagnostic accuracy of urinary LAM were determined.</p><p><strong>Results: </strong>Of 98 patients, 36 were diagnosed with GITB and 62 with CD. Urinary LAM was positive in nine out of 36 GITB patients, yielding a sensitivity of 25% (95% C.I. 12.12-42.20%) and a PPV of 100% (95% C.I. 66.37-100.00%). None of the CD patients tested positive for urinary LAM, resulting in a specificity of 100% (95% C.I. 94.22-100.00%) and NPV of 69.66% (95% C.I. 65.54-73.50%). Overall diagnostic accuracy of urinary LAM in differentiating GITB from CD was 72.45% (95% C.I. 62.54-80.99%). Notably, the addition of urinary LAM testing to the existing diagnostic criteria improved the accurate identification of GITB from 44% to 55.6%.</p><p><strong>Conclusion: </strong>Urinary LAM testing exhibits high specificity and PPV, making it a significant adjunct in the diagnostic process for GITB.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Refining the role of ROTEM in ulcerative colitis: A critical perspective. 改进ROTEM在溃疡性结肠炎中的作用:一个关键的观点。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-18 DOI: 10.1007/s12664-025-01819-y
Sukrati Maheswari, Suprabhat Giri
{"title":"Refining the role of ROTEM in ulcerative colitis: A critical perspective.","authors":"Sukrati Maheswari, Suprabhat Giri","doi":"10.1007/s12664-025-01819-y","DOIUrl":"https://doi.org/10.1007/s12664-025-01819-y","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inflammation-related polymorphisms IFNG-AS1 rs1558744 and CCAT2 rs6983267: Potential risk factors for ulcerative colitis. 炎症相关多态性IFNG-AS1 rs1558744和CCAT2 rs6983267:溃疡性结肠炎的潜在危险因素
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-18 DOI: 10.1007/s12664-025-01801-8
Dilek Sari-Tiric, Seda Orenay-Boyacioglu, Elmas Kasap
{"title":"Inflammation-related polymorphisms IFNG-AS1 rs1558744 and CCAT2 rs6983267: Potential risk factors for ulcerative colitis.","authors":"Dilek Sari-Tiric, Seda Orenay-Boyacioglu, Elmas Kasap","doi":"10.1007/s12664-025-01801-8","DOIUrl":"https://doi.org/10.1007/s12664-025-01801-8","url":null,"abstract":"<p><strong>Background: </strong>Recent research indicates that long non-coding RNAs (lncRNAs) may have a regulatory role in inflammatory processes, potentially influencing the development of inflammatory bowel diseases such as ulcerative colitis (UC). However, the relationship between UC and lncRNAs remains unclear, highlighting the need for further research in this area.</p><p><strong>Aim: </strong>This study aimed to define the possible roles of inflammation-related lncRNA polymorphisms in the pathogenesis of UC.</p><p><strong>Method: </strong>The study included adult patients over 18 years of age diagnosed with UC (n = 73) and a control group consisting of age-matched healthy individuals without any gastrointestinal complaints (n = 73). The inflammation-related ANRIL (rs10757278, rs1333048), IFNG-AS1 (rs1558744, rs7134599), LINC01430 (rs6017342), LOC101926945 (rs561722) and CCAT2 (rs6983267) polymorphisms were examined using the Fluidigm SNP Type method.</p><p><strong>Results: </strong>Of UC patients, 34.25% (n = 25) had proctitis, 28.77% (n = 21) had distal colon involvement and 36.98% (n = 27) had total colon involvement. Also, of the UC patients, 45.20% (n = 33) had suffered for 0-5 years, 41.10% (n = 30) for 5-10 years and 13.70% (n = 10) for 10-16 years. According to the pathology results of the most recent colonoscopy performed on UC patients, the disease was active in 60.27% (n = 44) and in remission in 39.73% (n = 29). The genotype distributions of the IFNG-AS1 rs1558744 and CCAT2 rs6983267 polymorphisms between the two groups revealed statistically significant results (p = 0.042 and p = 0.033, respectively). Allele frequency distributions of the IFNG-AS1 rs1558744 polymorphism between the UC and control groups were also statistically significant (p = 0.040). No statistically significant differences were observed when the examined polymorphisms were analyzed in relation to the location of involvement, disease activity state or disease duration in UC patients (p > 0.05).</p><p><strong>Conclusion: </strong>IFNG-AS1 rs1558744 and CCAT2 rs6983267 polymorphisms may be significant risk factors for the development of UC.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aneurysmal dilatation of small intestine in a case of untreated celiac disease with enteropathy associated T-Cell lymphoma. 未经治疗的乳糜泻伴肠病相关t细胞淋巴瘤一例小肠动脉瘤样扩张
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-18 DOI: 10.1007/s12664-025-01817-0
Jahnvi Dhar, Pankaj Gupta, Suvradeep Mitra, Jayanta Samanta
{"title":"Aneurysmal dilatation of small intestine in a case of untreated celiac disease with enteropathy associated T-Cell lymphoma.","authors":"Jahnvi Dhar, Pankaj Gupta, Suvradeep Mitra, Jayanta Samanta","doi":"10.1007/s12664-025-01817-0","DOIUrl":"https://doi.org/10.1007/s12664-025-01817-0","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perioperative versus adjuvant chemotherapy in carcinoma stomach-A retrospective propensity-matched analysis. 胃癌围手术期与辅助化疗的回顾性倾向匹配分析。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-18 DOI: 10.1007/s12664-025-01767-7
Archana Elangovan, Prasanth Penumadu, Biswajit Dubashi, N Sreekumaran Nair, Balasubramanian A
{"title":"Perioperative versus adjuvant chemotherapy in carcinoma stomach-A retrospective propensity-matched analysis.","authors":"Archana Elangovan, Prasanth Penumadu, Biswajit Dubashi, N Sreekumaran Nair, Balasubramanian A","doi":"10.1007/s12664-025-01767-7","DOIUrl":"https://doi.org/10.1007/s12664-025-01767-7","url":null,"abstract":"<p><strong>Background: </strong>A uniform consensus on the optimal sequencing of treatment modalities in locally advanced gastric cancer is not reached due to conflicting results worldwide. We conducted a retrospective propensity-matched analysis to compare survival of locally advanced gastric cancer patients who were treated with peri-operative chemotherapy followed by surgery or upfront surgery followed by adjuvant chemotherapy.</p><p><strong>Methods: </strong>Deidentified records of prospectively maintained data of locally advanced gastric cancer patients treated from 2015 to 2020 were collected. A 1:1 propensity matching with a tolerance limit of 0.2 was performed. The outcome variables including recurrence-free and overall survival were compared among the matched groups using log-rank tests and Cox proportional hazards analysis was performed.</p><p><strong>Results: </strong>Two hundred patients (64 in peri-operative chemotherapy and 136 in the upfront surgery group) were included in the study. Variables including age group, sex, gastric outlet obstruction, tumor site, clinical T stage and node positivity were used for matching. The median overall survival and recurrence-free survival were found to be 21.90 months (95% CI = 13.30-30.49) and 15.08 months (95% CI = 8.17-21.98), respectively, in the peri-operative chemotherapy arm and 18.70 months (95% CI = 11.88-25.51) and 13.49 months (95% CI = 6.76-20.21), respectively, in upfront surgery arm with no significant difference (median follow-up 42 months). Patients who presented with pallor had Borrmann type 4 on endoscopy, received lesser number of chemotherapy cycles, lymph node ratio was > 0.13 and perineural invasion were associated with worse overall survival and recurrence-free survival.</p><p><strong>Conclusion: </strong>In this real-world scenario, retrospective propensity-matched study, no difference was noted in overall survival and recurrence-free survival between patients who received peri-operative chemotherapy or upfront surgery followed by adjuvant chemotherapy in locally advanced gastric cancer.</p>","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intravenous iron in ulcerative colitis-Raising the (iron) bar. 溃疡性结肠炎静脉注射铁提高(铁)棒。
IF 2
Indian Journal of Gastroenterology Pub Date : 2025-06-14 DOI: 10.1007/s12664-025-01802-7
Jimmy K Limdi
{"title":"Intravenous iron in ulcerative colitis-Raising the (iron) bar.","authors":"Jimmy K Limdi","doi":"10.1007/s12664-025-01802-7","DOIUrl":"https://doi.org/10.1007/s12664-025-01802-7","url":null,"abstract":"","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144293689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信